Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Luca, A.
Right arrow Articles by Ortona, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Luca, A.
Right arrow Articles by Ortona, L.
Related Collections
Right arrow Viral infections
Right arrow HIV
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)

Neurology 2002;59:342-347
© 2002 American Academy of Neurology

Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals

A. De Luca, MD, B. C. Ciancio, MD, D. Larussa, MD, R. Murri, MD, A. Cingolani, MD, M. G. Rizzo, MD, M. L. Giancola, MD, A. Ammassari, MD and L. Ortona, MD

From the Istituto di Clinica delle Malattie Infettive (Drs. De Luca, Ciancio, Larussa, Murri, Cingolani, Rizzo, Ammassari, and Ortona), Università Cattolica S Cuore; and Istituto Nazionale per le Malattie Infettive "Spallanzani" IRCCS (Dr. Giancola), Roma, Italy.

Address correspondence and reprint requests to Andrea De Luca, MD, Istituto di Clinica delle Malattie Infettive, Università Cattolica del S Cuore, Largo Francesco Vito, 1 - 00168 Roma, Italy; e-mail: andreadeluca{at}rm.unicatt.it; andeluc@tin.it

Objective: To investigate in detail factors associated with independent replication of HIV-1 in CNS, and to predict its therapeutic control.

Methods: HIV RNA concentration was measured by PCR in 134 cross-sectional paired plasma and CSF samples from 95 patients infected with HIV-1 with various conditions, and in longitudinal CSF samples from 50 patients on antiretroviral treatment. Monocyte chemotactic protein (MCP)-1 was quantified in CSF by ELISA.

Results: High HIV RNA levels either in plasma or in CSF did not correlate with HIV RNA concentration in the paired biologic sample. A high CSF-to-plasma HIV RNA ratio, suggesting independent viral replication in the CNS, was associated with higher CSF viral load and higher CSF MCP-1 levels. Higher MCP-1 levels in the CSF were also associated with neurologic disorders and were not influenced by the use of highly active antiretroviral therapy (HAART). A higher number of antiretroviral drugs with CSF penetration correlated with a more profound CSF HIV-1 load reduction, independently from the use of HAART alone. Virologic suppression in CSF was predicted by a higher number of CSF-penetrating antiretrovirals and by the baseline CSF viral load, whereas lower baseline CD4 counts and higher MCP-1 levels were associated with increased risk of virologic failure.

Conclusions: Quantification of HIV RNA in CSF is clinically useful, particularly in patients with neurologic disorders. CSF penetration of antiretrovirals must be considered when choosing treatments, mainly in patients with higher CSF viral loads, advanced disease, and CNS disorders associated with significant macrophage activation.




This article has been cited by other articles:


Home page
 FocusHome page
K. Goodkin
Psychiatric Aspects of HIV Spectrum Disease
Focus, July 1, 2009; 7(3): 303 - 310.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Dou, C. B. Grotepas, J. M. McMillan, C. J. Destache, M. Chaubal, J. Werling, J. Kipp, B. Rabinow, and H. E. Gendelman
Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS
J. Immunol., July 1, 2009; 183(1): 661 - 669.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
B. Shiramizu, A. E. Williams, C. Shikuma, and V. Valcour
Amount of HIV DNA in Peripheral Blood Mononuclear Cells is Proportional to the Severity of HIV-1-Associated Neurocognitive Disorders
J Neuropsychiatry Clin Neurosci, February 1, 2009; 21(1): 68 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. Letendre, J. Marquie-Beck, E. Capparelli, B. Best, D. Clifford, A. C. Collier, B. B. Gelman, J. C. McArthur, J. A. McCutchan, S. Morgello, et al.
Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System
Arch Neurol, January 1, 2008; 65(1): 65 - 70.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Schifitto, M. P. McDermott, J. C. McArthur, K. Marder, N. Sacktor, D. R. McClernon, K. Conant, B. Cohen, L. G. Epstein, K. Kieburtz, et al.
Markers of immune activation and viral load in HIV-associated sensory neuropathy
Neurology, March 8, 2005; 64(5): 842 - 848.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. J. Sevigny, S. M. Albert, M. P. McDermott, J. C. McArthur, N. Sacktor, K. Conant, G. Schifitto, O. A. Selnes, Y. Stern, D. R. McClernon, et al.
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia
Neurology, December 14, 2004; 63(11): 2084 - 2090.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. C. McArthur, M. P. McDermott, D. McClernon, C. St Hillaire, K. Conant, K. Marder, G. Schifitto, O. A. Selnes, N. Sacktor, Y. Stern, et al.
Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy
Arch Neurol, November 1, 2004; 61(11): 1687 - 1696.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.